As. Moore et al., EVALUATION OF MITOXANTRONE FOR THE TREATMENT OF LYMPHOMA IN DOGS, Journal of the American Veterinary Medical Association, 204(12), 1994, pp. 1903-1905
Mitoxantrone was administered to 74 dogs with lymphoma at a dosage of
5.0 mg/m(2) of body surface, IV, every 3 weeks. Thirty-four dogs had f
ailed to respond to prior treatment with chemotherapeutic agents, whic
h included doxorubicin (33 dogs). The remaining 40 dogs had not receiv
ed prior treatment. Complete remission was determined in 19 of 74 dogs
(26%), 10 of which had not received prior treatment. The median durat
ion of remission for these 10 dogs was 94 days (range, 49 to 440 days,
with 2 dogs still alive at 370 and 440 days, respectively). Nine dogs
that had received prior treatment had complete remission that lasted
for a median of 126 days (range, 42 to 792 days, with 1 dog still aliv
e at 792 days). The combined remission rate (complete remission plus p
artial remission) was 41%. Toxicosis was minimal, developing in only 9
dogs and requiring hospitalization of 2 dogs. We concluded that the c
omplete remission rate ascertained when mitoxantrone was the only trea
tment administered was low, compared with treatments that invoked othe
r chemotherapeutic agents; however, the combined remission race of 41%
indicated that mitoxantrone may be beneficial in the treatment oi lym
phoma in dogs.